



Tim Wagenaar, Ph.D is a Group Head within the Oncology Department of Sanofi working in Cambridge, Massachusetts.

Tim received his Ph.D from the University of Maryland in virology and molecular biology and his undergraduate degree in biochemistry from the University of Iowa. Prior to joining Sanofi, he was a postdoctoral fellow at the University of Massachusetts Medical School studying the mechanism of resistance to BRAF kinase inhibitors in melanoma. Tim joined Sanofi in 2012 and over the past 6 years has held positions of increasing responsibility supporting several nucleic acid based therapeutics including microRNA and mRNA based modalities. In his current role Tim supports the Sanofi-BioNTech collaboration on mRNA based cancer immunotherapies therapeutics.